Hercules, CA — Bio-Rad Laboratories, Inc. today announced that it has launched the REDFIN 2-D gel analysis service. Novice and expert researchers can use the REDFIN service for professional analysis of 2-dimensional (2-D) gel electrophoresis experiments.

The REDFIN 2-D analysis service uses a downloadable software interface that researchers can use to quickly import their 2-D gel images. Then a team of REDFIN 2-D gel analysis experts analyze the uploaded images and return the results to the researcher.

With REDFIN 2-D analysis service, researchers no longer need to perform the tedious tasks of manually counting and aligning spots on their gels. REDFIN helps researchers who are getting started with 2-D analysis, providing them with guidance through the process as well as giving additional confidence in their final results.

“REDFIN 2-D analysis service will save 2-D gel electrophoresis users time by offering them an easy-to-use solution that yields faster results and peace of mind by having the analysis performed by experts,” said Katy McGirr, Product Manager, Lab Separations Division. “And with the ‘pay-as-you-go’ nature of the service, REDFIN analysis is a low-risk way for researchers to get started in 2-D gel experiments.”

The image analysis by REDFIN professionals consists of spot detection and segmentation, and spot matching, as well as quantification and normalization. The service ensures that the spot detection process is objective and unbiased and offers consistently reproducible results across multiple experiments.

The key benefits of the REDFIN 2-D service are:

An easy-to-use and navigate software interface

Versatility of using any 2-D stain, including DIGE and protein-specific stains

Convenience of performing advanced statistical calculations on the results with REDFIN software

Added data security: results are password protected and backed up by the REDFIN service

An easy way for researchers to share information via email

The REDFIN 2-D analysis service is a credit-based system. Researchers are able to pay as they go or pre-purchase credits for future projects. For most projects, researchers are able to choose the Basic service level (2 credits per gel) or they can select the Pro level (10 credits per gel) to remove streaks and artifacts and improve quality assurance for spot detection and matching. For more information about the REDFIN 2-D analysis service, please visit www.expressionproteomics.com/redfin.

The REDFIN 2-D analysis service is available through a partnership between Bio-Rad and Ludesi Corporation, a global bioinformatics company.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, and major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit https://www.bio-rad.com.

Information in this release applies specifically to products available in the United States. Product availability and specifications may vary in non-U.S. markets.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.